Integer Holdings Corporation (ITGR) Securities Class Action Lawsuit Filed [December 16, 2025]

Introduction to Integer Holdings Corporation (ITGR) Securities Class Action Lawsuit

A federal securities class action, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, has been filed on behalf of investors in Integer Holdings Corporation (NYSE: ITGR) common stock, NYSE: ITGR. The alleged class period runs from July 25, 2024 through October 22, 2025. Investors allege the Company and senior executives misrepresented Integer's competitive position in electrophysiology (EP) and in its Cardio & Vascular segment and overstated demand, repeatedly claiming the EP business was outgrowing the market with strong visibility into customer needs. The story reversed when, on October 23, 2025, Integer, in a corrective disclosure reducing full-year sales guidance to $1.50-$1.54 billion from $1.60-$1.64 billion, disclosed that two EP devices were adopting more slowly than forecast, with declines expected into 2026. The market reacted sharply, with a 32% single-day decline in the stock price, and shareholders suffered significant losses.

Integer Holdings Corporation (ITGR) Securities Lawsuit Case Details

Case Name: West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation et al.

Case No.: 1:25-cv-10251

Jurisdiction: U.S. District Court, Southern District of New York

Filed on: December 10, 2025

Integer Holdings Corporation (ITGR) Company Profile

Integer is a global medical device contract manufacturer, providing contract development and manufacturing services focused on cardiac rhythm management and cardiovascular products. Its Cardio & Vascular segment, which includes EP devices used to map the heart's electrical activity, supporting arrhythmia diagnosis and treatment in interventional cardiology and structural heart procedures, contributes roughly 60% of the Company's revenue.

Integer Holdings Corporation (ITGR) Securities Lawsuit Class Period

July 25, 2024 - October 22, 2025, inclusive.

All persons and entities that purchased Integer common stock (common stock purchasers) during the Class Period may be eligible to join the Integer Holdings Corporation (ITGR) class action lawsuit.

Allegations in the Integer Holdings Corporation (ITGR) Securities Class Action Lawsuit

The lawsuit names Integer Holdings Corporation, CEO Joseph W. Dziedzic, CFO Diron Smith, and COO Payman Khales, alleging securities fraud under the federal securities laws, including Sections 10(b) and 20(a). According to the complaint, these defendants portrayed Integer as a leader in a growing EP market, emphasizing visibility into demand and sustained outperformance, while overstating its competitive position and mischaracterizing EP as a long-term growth driver. The narrative begins on July 25, 2024, when CEO Dziedzic told investors in a press release that Integer expected 2024 above-market sales growth of 9% to 11% and raised adjusted operating income growth to 14% to 21%, calling the outlook proof of "successful execution." That same day on the earnings call, he said the Company was "confident" it could deliver strong sales growth given "high visibility to consumer demand," and he asserted the EP business was growing at roughly 1.5x the market growth rate, touting Integer's competitive position in electrophysiology devices. 

The message continued into late 2024 and 2025. On October 24, 2024, Dziedzic said EP "continues to outperform the market," again citing about 1.5x end-market growth on a trailing four-quarter basis with acceleration ahead as more products came to market, reinforcing EP as a purported growth driver for the Cardio & Vascular segment. On February 20, 2025, he stated Integer was still "outgrowing the market" in Electrophysiology and Structural Heart. And on April 24, 2025, he reaffirmed that EP "continues to outgrow the markets very nicely," highlighting Integer's participation across many steps in the procedure and industry volume as a growth driver. 

Behind these statements, investors allege a different picture. The complaint charges that Integer materially overstated its competitive position in EP and, despite claims of strong visibility, was experiencing sustained deterioration in sales tied to two EP devices, and failed to disclose material information to investors during the Class Period. According to the allegations, defendants mischaracterized EP as a long-term growth driver for the Cardio & Vascular segment, rendering their positive statements about business, operations, and prospects false or lacking a reasonable basis, and thereby misled investors.

The Truth Emerges

The alleged truth surfaced on October 23, 2025, when Integer issued a press release and held an earnings call cutting full-year 2025 sales guidance to $1.50-$1.54 billion, down from prior guidance of $1.60-$1.64 billion. Management told investors to expect 2026 net sales growth of -2% to 2% and organic sales growth of 0% to 4%, and disclosed that two EP devices had experienced slower than forecasted market adoption, indicating sustained demand weakness. COO Payman Khales stated the Company expected sales of three new products to decline in 2026, two of which were EP products, because adoption had been slower than forecast, reflecting deteriorating sales trends in those electrophysiology devices. CFO Diron Smith added that Cardio & Vascular sales growth would decelerate due to the decline in two new EP products, with the impact continuing into 2026, primarily in the first half, consistent with lowered sales guidance. 

These revelations, as a corrective disclosure, directly undercut months of assurances that EP outpaced the market at roughly 1.5x and would accelerate as products rolled out. The corrective disclosure linked Integer's revised outlook to weaker-than-expected demand for key EP devices, contradicting prior claims of strong visibility and durable growth and aligning with investors' claims of material misstatements and omissions.

Market Reaction

Before markets opened on October 23, 2025, Integer revealed, in a corrective disclosure, the guidance cut and weaker EP adoption. By the close that day, the stock fell $35.22 per share, from a prior close of $109.11 to $73.89, a 32% single-day stock price decline. The decline reflected the market's reassessment of Integer's EP growth narrative in light of management's admissions and revised outlook under the federal securities laws.

Next Steps

• Submissions for lead plaintiff are due: February 9, 2026.

• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

• The Court will then consider motion for class certification.

• The Court will later consider a Motion to Dismiss.

To learn if you are eligible for recovery under the ITGR securities class action lawsuit, visit the case submission page here.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.